Helus Pharma (STU:R7E) GF Score: 38/100 (As of Jul. 20, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:R7E Helus Pharma Inc STU:R7E
38 GF Score
Price €6.39
! 2 Warning Signs
View Full Analysis

What is Helus Pharma GF Score?

Helus Pharma STU:R7E +2.73% 38 GF Score is 38 as of Jul. 20, 2026, which is 9% above its 10-year median of 35.00. GuruFocus rates STU:R7E with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Helus Pharma has the GF Score of 38, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 9/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Helus Pharma might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Helus Pharma  (STU:R7E) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Helus Pharma GF Score Related Terms

STU:R7E vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Helus Pharma's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helus Pharma GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helus Pharma's GF Score distribution charts can be found below:

* The bar in red indicates where Helus Pharma's GF Score falls into.


STU:R7E
38GF Score
Helus Pharma Inc STU:R7E
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 38 mean?
Helus Pharma (STU:R7E) has a GF Score of 38 as of Jul. 20, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Helus Pharma and its competitors. This is near median its historical median of 35.00. Over the past decade, Helus Pharma's GF Score has ranged from 13.00 to 42.00.
Is Helus Pharma's GF Score too high?
Helus Pharma's current GF Score of 38 is near median its 10-year median of 35.00. Over the past 10 years, this metric has ranged from a low of 13.00 to a high of 42.00. Overall, Helus Pharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's GF Score compare to VRTX and REGN?
Helus Pharma's GF Score of 38 can be compared against companies in the Biotechnology industry. Historically, Helus Pharma's own GF Score has ranged from 13.00 to 42.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Helus Pharma and its competitors. Helus Pharma's current GF Score is 38, which is near median its own 10-year median of 35.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (STU:R7E) has a current GF Score of 38. The current GF Score is 38, which is near median its 10-year median of 35.00. Helus Pharma's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Helus Pharma (STU:R7E), the current GF Score is 38 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges HELP:USAHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
38GF Score

Get the complete analysis for STU:R7E

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.39
Price